Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Moser, H. W.
Right arrow Articles by Kishimoto, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Moser, H. W.
Right arrow Articles by Kishimoto, Y.
NEUROLOGY 1981;31:1241
© 1981 American Academy of Neurology

Adrenoleukodystrophy

Increased plasma content of saturated very long chain fatty acids

Hugo W. Moser, M.D., Ann B. Moser, A.B., Karen K. Frayer, A.B., Winston Chen, Ph.D., Joseph D. Schulman, M.D., Brian P. O'Neill, M.D. and Yasuo Kishimoto, Ph.D.

John F. Kennedy Institute (Drs. Moser, Chen, and Kishimoto, Ms. Moser, and Ms. Frayer), the Departments of Neurology and Pediatrics, Johns Hopkins University (Dr. Maser), the National Institutes of Health, Child Health and Human Development (Dr. Schulmanl, and the Department of Neurology, Maya Clinic and Foundation (Dr. O'Neill), Rochester, MN.

With a new method we measured the saturated very long chain fatty acids in the plasma of adrenoleukodystrophy (ALD) hemizygotes, ALD heterozygotes, and controls. ALD hemizygotes showed increased levels of hexacosanoate (C26 fatty acid) which represented 0.081 2 0.0066% (SEM) of total Fatty acids, compared to 0.015 ± 0.0032% in the controls. C25, C24, and C23 fatty acids were also increased, but the C22 and C20 fatty acids were normal. C26 levels were also increased in most ALD heterozygotes, with a mean level 0.057 2 0.0063% of total fatty acids. The technique can be used for diagnosis and carrier identification, and in the evaluation of therapy.

Address correspondence and reprint requests to Dr. Moser, John F. Kennedy Institute, 707 N. Broadway, Baltimore, MD 21205.

Supported in part by Grants HD 10981 and NS 10885 and 13513 from the Public Health Service and by Grant 6-271 from the National Foundation-March of Dimes.

Accepted for publication February 11, 1981




This article has been cited by other articles:


Home page
 FASEB J.Home page
R.-J. Sanders, R. Ofman, G. Dacremont, R. J. A. Wanders, and S. Kemp
Characterization of the human {omega}-oxidation pathway for {omega}-hydroxy-very-long-chain fatty acids
FASEB J, June 1, 2008; 22(6): 2064 - 2071.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
G. V. Raymond
Hugo W. Moser, MD (1924-2007)
Arch Neurol, May 1, 2007; 64(5): 758 - 759.
[Full Text] [PDF]

Home page
 J. Lipid Res.Home page
M. Y. Golovko and E. J. Murphy
Uptake and metabolism of plasma-derived erucic acid by rat brain
J. Lipid Res., June 1, 2006; 47(6): 1289 - 1297.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
I. Oezen, W. Rossmanith, S. Forss-Petter, S. Kemp, T. Voigtlander, K. Moser-Thier, R. J. Wanders, R. E. Bittner, and J. Berger
Accumulation of very long-chain fatty acids does not affect mitochondrial function in adrenoleukodystrophy protein deficiency
Hum. Mol. Genet., May 1, 2005; 14(9): 1127 - 1137.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
J.-K. Choi, J. Ho, S. Curry, D. Qin, R. Bittman, and J. A. Hamilton
Interactions of very long-chain saturated fatty acids with serum albumin
J. Lipid Res., July 1, 2002; 43(7): 1000 - 1010.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
B M van Geel, J Assies, E B Haverkort, J H T M Koelman, B Verbeeten Jr, R J A Wanders, and P G Barth
Progression of abnormalities in adrenomyeloneuropathy and neurologically asymptomatic X-linked adrenoleukodystrophy despite treatment with "Lorenzo's oil"
J. Neurol. Neurosurg. Psychiatry, September 1, 1999; 67(3): 290 - 299.
[Abstract] [Full Text]

Home page
 Arch NeurolHome page
H. Takano, R. Koike, O. Onodera, R. Sasaki, and S. Tsuji
Mutational Analysis and Genotype-Phenotype Correlation of 29 Unrelated Japanese Patients With X-linked Adrenoleukodystrophy
Arch Neurol, March 1, 1999; 56(3): 295 - 300.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
J.-F. Lu, A. M. Lawler, P. A. Watkins, J. M. Powers, A. B. Moser, H. W. Moser, and K. D. Smith
A mouse model for X-linked adrenoleukodystrophy
PNAS, August 19, 1997; 94(17): 9366 - 9371.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
B. M van Geel, J. Assies, R. J A Wanders, and P. G Barth
X linked adrenoleukodystrophy: clinical presentation, diagnosis, and therapy
J. Neurol. Neurosurg. Psychiatry, July 1, 1997; 63(1): 4 - 14.
[Abstract] [Full Text] [PDF]

Home page
 J Child NeurolHome page
H. W. Moser
Adrenoleukodystrophy: From Bedside to Molecular Biology
J Child Neurol, April 1, 1987; 2(2): 140 - 150.
[Abstract] [PDF]

Home page
 Arch NeurolHome page
R. S. K. Young, J. C. Ramer, J. Towfighi, W. Weidner, R. Lehman, and H. W. Moser
Adrenoleukodystrophy: Unusual Computed Tomographic Appearance
Arch Neurol, December 1, 1982; 39(12): 782 - 783.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1981 by AAN Enterprises, Inc.